Extended Data Fig. 9: BBI-2779 has optimal PK exposure in mice.
From: Enhancing transcription–replication conflict targets ecDNA-positive cancers
Plasma concentration time curve of BBI-2779 in mouse administered either intravenously (IV) at 2 mg kg−1 or orally (PO) at 30 mg/kg−1. Data are mean ± s.e.m., n = 3 per group.
